Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Withdrawn 3Terminated 3Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Multiple Myeloma 20Lymphoma 17Neoplasm Metastasis 14Leukemia, Myeloid, Acute 12Pancreatic Neoplasms 9Breast Neoplasms 9Ovarian Neoplasms 8Melanoma 8Lung Neoplasms 8Colorectal Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Glioma 7Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Neuroblastoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Endometrial Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Ependymoma 5Burkitt Lymphoma 5Wilms Tumor 4Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rhabdomyosarcoma 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4

Interventions

pembrolizumab 10Cisplatin 7Radiotherapy 6Magnetic Resonance Spectroscopy 6Carboplatin 6Specimen Handling 5Paclitaxel 5Brachytherapy 5Fluorodeoxyglucose F18 4dostarlimab 3atezolizumab 3Trastuzumab 3Radiation 3Platinum 3Nivolumab 3Human Papillomavirus DNA Tests 3Docetaxel 3Colposcopy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tislelizumab 2spartalizumab 2olaparib 2human papillomavirus vaccine, L1 type 16, 18 2durvalumab 2Vaccines 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiation Dose Hypofractionation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Cervical Neoplasms × Biopsy × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡